Amgen Inc (BSP:AMGN34)
R$ 58.14 0 (0%) Market Cap: 881.03 Bil Enterprise Value: 1.20 Til PE Ratio: 34.15 PB Ratio: 19.04 GF Score: 86/100

Amgen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 05:40PM GMT
Release Date Price: R$50.24
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay. Welcome to the afternoon sessions of day 3 of the BofA Virtual Vegas Global Health Care Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. And I have Aspen Mori from my team as well on the line.

We're thrilled to have Amgen present this afternoon. And speaking on behalf of Amgen, we have Peter Griffith, CFO. We have Murdo Gordon, Head of Global Commercial Operations; and then Arvind Sood from the IR team.

Peter and Murdo, are you guys there?

Peter H. Griffith
Amgen Inc. - Executive VP & CFO

We sure are.

Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay. Great. So the first thing we're going to do is I'll ask Peter and Murdo to have -- just say something at the onset here just to set up the stage. We have some questions and, of course, there are the ability to, on the Veracast system, to also type us a question and we can ask

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot